3-(氯甲基)-4-羟基-5-甲氧基苯甲醛 | 28276-04-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 3-(氯甲基)-4-羟基-5-甲氧基苯甲醛
• 英文名称: 5-(chloromethyl)vanillin
• 英文别名: 5-Chlormethyl-vanillin；3-(chloromethyl)-4-hydroxy-5-methoxybenzaldehyde；3-Chlormethyl-4-hydroxy-5-methoxy-benzaldehyd；5-chloromethyl-4-hydroxy-3-methoxybenzaldehyde
• CAS: 28276-04-2
• 化学式: C₉H₉ClO₃
• mdl: MFCD03011574
• 分子量: 200.622
• InChiKey: LNACAWAKOKCCKX-UHFFFAOYSA-N

物化性质

• 熔点：
  120-122 °C
• 沸点：
  347.2±42.0 °C(Predicted)
• 密度：
  1.326±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(氯甲基)-4-羟基-5-甲氧基苯甲醛 在 tin(II) chloride dihdyrate 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以35.2%的产率得到4-hydroxy-3-methoxy-5-methylbenzaldehyde
  参考文献：
  名称：

  四氢黄连碱衍生物及其应用

  摘要：

  本发明涉及式(VII)化合物和制备方法及其在医药上的应用。具体而言，本发明涉及通式为(VII)化合物的衍生物和制备方法以及其作为治疗剂，在预防和治疗高脂血症，高胆固醇血症，高甘油三酯血症，肝脂肪变性，II型糖尿病，高血糖症，肥胖症或胰岛素抵抗症和代谢综合征中的用途。本文公开的化合物还能降低总胆固醇、LDL-胆固醇和甘油三酯，并且增加肝LDL受体表达、下调PCSK9表达。

  公开号：

  CN105418601A
• 作为产物：
  描述：

  3-(ethanoyloxymethyl)-4-hydroxy-5-methoxybenzaldehyde 在 盐酸 作用下， 以 水 为溶剂， 反应 2.0h， 生成 3-(氯甲基)-4-羟基-5-甲氧基苯甲醛
  参考文献：
  名称：

  四氢黄连碱衍生物及其应用

  摘要：

  本发明涉及式(VII)化合物和制备方法及其在医药上的应用。具体而言，本发明涉及通式为(VII)化合物的衍生物和制备方法以及其作为治疗剂，在预防和治疗高脂血症，高胆固醇血症，高甘油三酯血症，肝脂肪变性，II型糖尿病，高血糖症，肥胖症或胰岛素抵抗症和代谢综合征中的用途。本文公开的化合物还能降低总胆固醇、LDL-胆固醇和甘油三酯，并且增加肝LDL受体表达、下调PCSK9表达。

  公开号：

  CN105418601A

文献信息

• [EN] NOVEL MODULATORS OF PROTEIN KINASE SIGNALING<br/>[FR] NOUVEAUX MODULATEURS DE LA SIGNALISATION DE PROTÉINES KINASES
  申请人：NOVOTYR THERAPEUTICS LTD

  公开号：WO2009147682A1

  公开（公告）日：2009-12-10

  The present invention provides new tyrphostin derivatives acting as protein kinase (PK) and receptor kinase (RK) signaling modulators. The invention further provides methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PK and RK related disorders such as metabolic, inflammatory, fibrotic, and cell proliferative disorders, in particular cancer.

  本发明提供了新的酪氨酸激酶抑制剂衍生物，可作为蛋白激酶（PK）和受体激酶（RK）信号调节剂。该发明还提供了它们的制备方法，包括这些化合物的药物组合物，以及使用这些化合物和组合物的方法，特别是作为化疗药物，用于预防和治疗PK和RK相关疾病，如代谢性、炎症性、纤维化和细胞增殖性疾病，特别是癌症。
• Specific inhibitors of tyrosine-specific protein kinase. I. Synthesis and inhibitory activities of .ALPHA.-cyanocinnamamides.
  作者：TADAYOSHI SHIRAISHI、KEIJI KAMEYAMA、NAOHIRO IMAI、TAKESHI DOMOTO、IKUO KATSUMI、KIYOSHI WATANABE

  DOI：10.1248/cpb.36.974

  日期：——

  A series of α-cyanocinnamamide derivatives was synthesized and evaluated for inhibitory activity against tyrosine-specific protein kinase using intact plasma membrane fractions from an epidermoid carcinoma cell line, A-431 cells. Among these compounds, several novel α-cyano-4-hydroxy-3, 5-disubstituted cinnamamide derivatives, e.g., α-cyano-3-ethoxy-4-gtdrixt-5-phenyl-thiomethylcinnamamide (ST 638), showed potent inhibitory activity. The studies on the structure-activity relationship revealed that the presence of the hydroxy group at the 4 position and the double bond in the α-cyano-4-hydroxycinnamamide skeleton was important for potent inhibitory activity, and that the presence of hydrophobic groups at the 3 and 5 positions on the benzene ring also enhanced the inhibitory activity of α-cyano-4-hydroxycinnamamide derivatives.

  合成了一系列α-氰基肉桂酰胺衍生物，并使用来自表皮癌细胞系A-431细胞的完整细胞膜分馏评估其对酪氨酸特异性蛋白激酶的抑制活性。在这些化合物中，几种新型的α-氰基-4-羟基-3, 5-二取代肉桂酰胺衍生物，如α-氰基-3-乙氧基-4-二甲基-5-苯基-硫甲基肉桂酰胺（ST 638），表现出强大的抑制活性。关于结构-活性关系的研究表明，在α-氰基-4-羟基肉桂酰胺骨架中，4位的羟基和双键的存在对于有效的抑制活性至关重要，而在苯环的3位和5位上存在疏水基团也增强了α-氰基-4-羟基肉桂酰胺衍生物的抑制活性。
• NOVEL MODULATORS OF PROTEIN KINASE SIGNALING
  申请人：Reuveni Hadas

  公开号：US20110105618A1

  公开（公告）日：2011-05-05

  The present invention provides new tyrphostin derivatives acting as protein kinase (PK) and receptor kinase (RK) signaling modulators. The invention further provides methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PK and RK related disorders such as metabolic, inflammatory, fibrotic, and cell proliferative disorders, in particular cancer.

  本发明提供了新的酪氨酸激酶（PK）和受体激酶（RK）信号调节剂的酪氨酸激酶抑制剂衍生物。本发明还提供了其制备方法，包括这些化合物的制药组合物，以及使用这些化合物和组合物的方法，特别是作为化疗药物，用于预防和治疗PK和RK相关疾病，如代谢性、炎症性、纤维化和细胞增生性疾病，特别是癌症。
• Tyrphostins. 3. Structure-activity relationship studies of .alpha.-substituted benzylidenemalononitrile 5-S-aryltyrphostins
  作者：Aviv Gazit、Nir Osherov、Israel Posner、Allan Bar-Sinai、Chaim Gilon、Alexander Levitzki

  DOI：10.1021/jm00075a010

  日期：1993.11

  In this study we describe an extension of our previous studies on cis-benzylidenemalononitrile tyrphostins. We have introduced S-aryl substituents in the 5 position (meta vis-a-vis the malononitrile moiety). We find that these compounds are potent blockers of EGFR kinase and its homolog HER-2 kinase. Interestingly, we find that certain S-aryltyrphostins discriminate between EGFR and HER-2 kinase in favor of the HER-2 kinase domain by almost 2 orders of magnitude. When examined in intact cells it was found that these selective S-aryltyrphostins are equipotent in inhibiting EGF dependent proliferation of NIH 3T3 harboring either the EGF receptor or the chimera EGF/neu (HER1-2). These findings suggest that the antiproliferative activity of these tyrphostins is mainly due to the inhibition of a mitogenic signaling element downstream to the growth receptor kinase.
• An expeditious and convergent synthesis of ailanthoidol
  作者：Maddali L.N. Rao、Dheeraj K. Awasthi、Debasis Banerjee

  DOI：10.1016/j.tetlet.2010.02.018

  日期：2010.4

  An expeditious and concise method has been described for the synthesis of ailanthoidol through convergent route starting from vanillin. The protocol involving intramolecular Wittig as a key reaction afforded ailanthoidol in overall high yield. (C) 2010 Elsevier Ltd. All rights reserved.